Summary
SENS Chart
Here's Why Senseonics (SENS) is Poised for a Turnaround After Losing 5.7% in 4 Weeks
The heavy selling pressure might have exhausted for Senseonics (SENS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement
GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of a total of 115,000,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase up to an additional 15,000,000 shares of common stock, at a public offering price of $0.50 per share.
Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity
I share my recent interview with Senseonics CEO, Tim Goodnow and the CFO, Rick Sullivan. Senseonics has recently introduced a 365-day Continuous Glucose Monitoring system, aiming to disrupt a market dominated by short-term CGMs from DexCom, Abbott Laboratories, and Medtronic. The next 12 months will be crucial for Senseonics as they prove their technology and decide if they continue their commercial partnership with Ascensia, change partners to go solo.
Senseonics Holdings Inc. Dividends
Senseonics Holdings Inc. Earnings
| 22 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 20 May 2024 Date | | - Cons. EPS | - EPS |
| 22 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 20 May 2024 Date | | - Cons. EPS | - EPS |
Senseonics Holdings Inc. (SENS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Senseonics Holdings Inc. ever had a stock split?
Senseonics Holdings Inc. Profile
| Medical - Devices Industry | Healthcare Sector | Dr. Timothy T. Goodnow Ph.D. CEO | AMEX Exchange | 81727U105 Cusip |
| US Country | 117 Employees | - Last Dividend | 10 Nov 2015 Last Split | 17 Mar 2016 IPO Date |
Overview
Senseonics Holdings, Inc. is a medical technology entity dedicated to advancing diabetes care through its innovative continuous glucose monitoring (CGM) solutions. Founded in 1996, with its headquarters set in Germantown, Maryland, Senseonics has been at the forefront of offering advanced CGM systems, tailored for individuals living with diabetes across the United States, Europe, the Middle East, and Africa. The company's primary commitment is to enhance the quality of diabetes management for its users, allowing for real-time and accurate glucose level monitoring, fundamentally changing how people with diabetes manage their condition. Senseonics not only develops and commercializes these CGM systems but also ensures their accessibility to healthcare providers and patients via a robust network of distributors and strategic fulfillment partners. Additionally, the company values collaborative efforts for innovation, as manifested in its partnership with the University Hospitals Accountable Care Organization, aiming to elevate care delivery and outcomes for those managing diabetes.
Products and Services
Eversense
As the initial offering in Senseonics' product line, the Eversense CGM system represents a breakthrough in diabetes management technology. This system is renowned for incorporating an under-the-skin sensor that continuously tracks glucose levels, thus providing real-time, accurate readings. Paired with a removable and rechargeable smart transmitter, Eversense amplifies the convenience and efficiency of monitoring glucose levels, offering a seamless diabetes management experience.
Eversense XL
Building upon the foundation laid by the original Eversense system, the Eversense XL extends the capabilities of continuous glucose monitoring with an enhanced duration of its under-the-skin sensor. Designed for long-term diabetes management, the Eversense XL aims to provide an even more convenient and less intrusive experience for users, reducing the frequency of sensor replacements and thereby improving the overall quality of life for individuals managing their glucose levels.
Eversense E3
The latest innovation in Senseonics' portfolio, the Eversense E3 CGM system, propels glucose monitoring to new heights with a sensor capable of providing accurate glucose measurements for up to six months. This extended duration underscores Senseonics' commitment to advancing diabetes care by minimizing the intrusion and maintenance associated with diabetes management. The Eversense E3 system combines the enduring accuracy of its sensor technology with a user-friendly app and a smart transmitter, ensuring that users have access to real-time glucose data at their fingertips, empowering them to make informed decisions about their diabetes management.
Contact Information
